[go: up one dir, main page]

WO2010007376A3 - Compositions monovalent for cd28 binding and methods of use - Google Patents

Compositions monovalent for cd28 binding and methods of use Download PDF

Info

Publication number
WO2010007376A3
WO2010007376A3 PCT/GB2009/001762 GB2009001762W WO2010007376A3 WO 2010007376 A3 WO2010007376 A3 WO 2010007376A3 GB 2009001762 W GB2009001762 W GB 2009001762W WO 2010007376 A3 WO2010007376 A3 WO 2010007376A3
Authority
WO
WIPO (PCT)
Prior art keywords
single variable
variable domain
monovalent
antibody single
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/001762
Other languages
French (fr)
Other versions
WO2010007376A2 (en
Inventor
Carolyn Enever
Steven Grant
David Sansom
Steve Holmes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Domantis Ltd
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Priority to JP2011517992A priority Critical patent/JP2012507260A/en
Priority to EP09784717A priority patent/EP2315778A2/en
Publication of WO2010007376A2 publication Critical patent/WO2010007376A2/en
Publication of WO2010007376A3 publication Critical patent/WO2010007376A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a monovalent anti-CD28 antibody single variable domain to the individual.
PCT/GB2009/001762 2008-07-18 2009-07-17 Compositions monovalent for cd28 binding and methods of use Ceased WO2010007376A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2011517992A JP2012507260A (en) 2008-07-18 2009-07-17 Monovalent compositions for CD28 binding and methods of use
EP09784717A EP2315778A2 (en) 2008-07-18 2009-07-17 Compositions monovalent for cd28 binding and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US755308P 2008-07-18 2008-07-18
US17603608A 2008-07-18 2008-07-18
US61/007,553 2008-07-18
US12/176,036 2008-07-18

Publications (2)

Publication Number Publication Date
WO2010007376A2 WO2010007376A2 (en) 2010-01-21
WO2010007376A3 true WO2010007376A3 (en) 2010-05-27

Family

ID=41316544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001762 Ceased WO2010007376A2 (en) 2008-07-18 2009-07-17 Compositions monovalent for cd28 binding and methods of use

Country Status (4)

Country Link
EP (1) EP2315778A2 (en)
JP (1) JP2012507260A (en)
AR (1) AR073459A1 (en)
WO (1) WO2010007376A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
ES2857226T3 (en) 2014-03-15 2021-09-28 Novartis Ag Regulable chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CN106397592A (en) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof
SG10201911035QA (en) 2015-11-18 2020-01-30 Merck Sharp & Dohme Pd1 and/or lag3 binders
HK1254952A1 (en) * 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Ctla4 binders
JP7022993B2 (en) * 2016-01-11 2022-02-21 インヒブルクス インコーポレイテッド Multivalued and multispecific 41BB binding fusion protein
CN107400166A (en) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 for CTLA4 single domain antibody and its derived protein
KR20210035805A (en) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Increased immune activity through regulation of postcellular signaling factors
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN117534761B (en) * 2023-11-20 2024-10-08 上海百英生物科技股份有限公司 An anti-CD28 nano antibody and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249700A1 (en) * 1995-07-25 2005-11-10 Allison James P Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO2006030220A1 (en) * 2004-09-17 2006-03-23 Domantis Limited Compositions monovalent for cd40l binding and methods of use
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249700A1 (en) * 1995-07-25 2005-11-10 Allison James P Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO2006030220A1 (en) * 2004-09-17 2006-03-23 Domantis Limited Compositions monovalent for cd40l binding and methods of use
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies

Also Published As

Publication number Publication date
WO2010007376A2 (en) 2010-01-21
AR073459A1 (en) 2010-11-10
JP2012507260A (en) 2012-03-29
EP2315778A2 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
WO2010007376A3 (en) Compositions monovalent for cd28 binding and methods of use
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
EA201100239A1 (en) MONOTARY COMPOSITIONS IN CONNECTION OF CD28 BINDING AND METHODS OF THEIR APPLICATION
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
AU2016219704A1 (en) Anti-Notch1 antibodies
TN2012000555A1 (en) Antibodies to human gdf8
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
GEP20125471B (en) Compositions monovalent for cd40l binding and methods of use
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2013033626A3 (en) Nkp30 receptor targeted therapeutics
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EP4269563A3 (en) Anti-gd2 antibodies
MX350355B (en) Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a.
EP3974453A3 (en) Agents and methods for treating diseases that correlate with bcma expression
WO2010036959A3 (en) Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
WO2012149412A3 (en) Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012007880A3 (en) Modified single domain antigen binding molecules and uses thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MY156353A (en) Methods of treating autoimmune diseases with dll4 antagonists
WO2010042636A3 (en) Telomerase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784717

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011517992

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009784717

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE